- Home
- GMAB vs DRI Comparison
GMAB vs DRI Comparison
Compare GMAB & DRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- DRI
- Stock Information
- Founded
- GMAB 1999
- DRI 1968
- Country
- GMAB Denmark
- DRI United States
- Employees
- GMAB N/A
- DRI N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- DRI Restaurants
- Sector
- GMAB Health Care
- DRI Consumer Discretionary
- Exchange
- GMAB Nasdaq
- DRI Nasdaq
- Market Cap
- GMAB 15.0B
- DRI 17.0B
- IPO Year
- GMAB N/A
- DRI 1995
- Fundamental
- Price
- GMAB $20.45
- DRI $162.57
- Analyst Decision
- GMAB Buy
- DRI Buy
- Analyst Count
- GMAB 8
- DRI 25
- Target Price
- GMAB $43.00
- DRI $180.12
- AVG Volume (30 Days)
- GMAB 1.5M
- DRI 1.1M
- Earning Date
- GMAB 11-06-2024
- DRI 12-13-2024
- Dividend Yield
- GMAB N/A
- DRI 3.46%
- EPS Growth
- GMAB 14.35
- DRI 7.72
- EPS
- GMAB 10.80
- DRI 8.66
- Revenue
- GMAB $2,967,926,227.00
- DRI $11,416,400,000.00
- Revenue This Year
- GMAB $30.31
- DRI $7.56
- Revenue Next Year
- GMAB $16.49
- DRI $7.85
- P/E Ratio
- GMAB $18.39
- DRI $18.77
- Revenue Growth
- GMAB 17.75
- DRI 5.98
- 52 Week Low
- GMAB $20.37
- DRI $135.87
- 52 Week High
- GMAB $32.88
- DRI $176.84
- Technical
- Relative Strength Index (RSI)
- GMAB 25.28
- DRI 47.25
- Support Level
- GMAB $20.50
- DRI $165.63
- Resistance Level
- GMAB $23.47
- DRI $171.21
- Average True Range (ATR)
- GMAB 0.45
- DRI 3.72
- MACD
- GMAB -0.18
- DRI -0.50
- Stochastic Oscillator
- GMAB 2.74
- DRI 28.48
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About DRI Darden Restaurants Inc.
Darden Restaurants is the largest restaurant operator in the us full-service space, with consolidated revenue of $11.4 billion in fiscal 2024 resulting in 3%-4% full-service market share (per NRA data and our calculations). The company maintains a portfolio of 10 restaurant brands: Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Ruth's Chris, Yard House, The Capital Grille, Seasons 52, Eddie V's, Bahama Breeze, and The Capital Burger. Darden generates revenue almost exclusively from company-owned restaurants, though a small network of franchised restaurants and consumer-packaged goods sales through the traditional grocery channel contribute modestly. As of the end of its fiscal 2024, the company operated 2,031 restaurants in the us.